Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Abstract: A flaky pigment excellent in leafing properties and in adhesion between pigment particles and a coating (resin) was obtained by coating the surface of a flaky pigment with a coupling agent and a phosphate having a perfluoroalkly group or a silane compound. Accordingly, the flaky pigment is excellent as a pigment for coating or printing ink of which brightness and durability are required.

Abstract: The present invention relates to intensely colored red effect pigments comprising iron oxide-coated SiO2 flakes, where the total thickness of the effect pigments is not greater than 500 nm (+/?30 nm). The present invention likewise relates to processes for the preparation of these pigments in which SiO2 flakes are coated with iron oxide, where the thicknesses of the SiO2 flakes and of the iron-oxide layers are selected in such a way that the total thickness of the red effect pigments is not greater than 500 nm (+/?30 nm), and to the use of these pigments in cosmetics, paints, coatings, plastics, films, in security printing, in security features in documents and identity papers, for coloring seed, for coloring foods or in medicament coatings and for the preparation of pigment compositions and dry preparations.

Abstract: The present invention relates to methods and compositions for using photostabilizer compounds for stabilizing formulation ingredients, like flavors, fragrances, colors, antioxidants, polymers, within cosmetics, personal care and household products, against degradation from sun light, heat and air oxidation resulting in improvement in storage stability, viscosity, and maintenance of color of the formulated products.

Abstract: Novel biphenyl derivatives of the general formula I in which R1, R1?, R1?, R2, R2?, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the ?v?6 integrin receptor.

Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS

Abstract: Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5?, X, Y, B, m, n and o are as defined in Patent Claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumors. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.

Abstract: The invention relates to liquid crystal compounds of formula (I), where X1, X2, X3, Z1, Z2, L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and a have the meanings given in claim 1, and liquid crystal media containing at least one compound of formula (I) and electro-optical displays comprising such a liquid crystal medium

Abstract: The present invention relates to a process for preparing highly pure tris-ortho-metallated organoiridium compounds and such pure organometallic compounds, especially compounds of the d8 metals, which may find use as coloring components in the near future, as active components (=functional materials) in a series of different types of application which can be classed within the electronic industry in the broadest sense.

Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: The invention relates to a preparation having light-protection properties comprising at least one compound of the formula I where R1 and R2 are selected from H and OR11, where each OR11, independently of the others, is OH, a straight-chain or branched C1- to C20-alkoxy group, a straight-chain or branched C3- to C20-alkenyloxy group, a straight-chain or branched C1- to C20-hydroxyalkoxy group, where the hydroxyl group(s) may be bonded to a primary or secondary carbon atom in the chain and furthermore the alkyl chain may also be interrupted by oxygen, and/or a C3- to C10-cycloalkoxy group and/or C3- to C12-cyclo-alkenyloxy group, where the rings may each also be bridged by —(CH2)n— groups, where n=1 to 3, and/or a mono- and/or oligoglycosyl radical, with the proviso that at least one radical from R1 and R2 is OR11, and R3 is a radical OR11, and R4 to R7 and R10 may be identical or different and are, independently of one another, radicals which are substantially inert with respect to the UV properties.

Abstract: HUTUDO1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods utilizing HUTUDO1 polypeptides and polynucleotides in diagnostic assays.

Abstract: Mono-, oligo- or polymers comprising at least one 9-H,H-fluorene group and at least one arylene group are suitable for use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices.

Abstract: The invention relates to multireactive polymerizable mesogenic compounds of formula I R1—MG—R2 I wherein R1, R2 and MG have the meaning given in claim 1, to a polymerizable mesogenic composition comprising at least two components, at least one which is a compound of formula I, to a linear or crosslinked polymer obtainable by polymerization of one or more compounds of formula I or of a polymerizable composition comprising one or more compounds of formula I and to the use of a compound of formula I, or a polymerizable composition or polymer obtainable thereof, in optical elements such as polarizers, optical retardation or compensation films, alignment layers, colour filters or holographic elements, in liquid crystal displays such as PDLC, polymer gel or polymer stabilized cholesteric texture (PSCT) displays, in adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics or liquid crystal pigments, for decorative and security applications, and for nonlinear optics or optical info

Abstract: The present invention relates to novel organometallic compounds which are phosphorescence emitters. Compounds of this type can be used as active components (=functional materials) in a series of different types of, application which can be classed within the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (I), (Ia), (II), (IIa), (V), (VII), (IX), (XI), (XIII) and (XV).

Abstract: The invention relates to indanes having negative ?? of the formula Ia or Ib in which R, A, Z, X, Y, V, W, n and m are as defined in claim 1. The compounds are particularly suitable for producing VA-TFT displays.

Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.

Abstract: The invention relates to new reactive mesogenic azulene derivatives, their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive mesogenic azulenes.

Abstract: The present invention relates to formulations for topical applications comprising pigments obtainable by agitating a suspension comprising one or more inorganic pigments and silver oxide, in order to reduce undesirable side effects caused by microorganisms.

Abstract: Aldehydes containing a difluorooxymethylene bridge, of the general formula I OHC-(A11)m-Z11-(A12-Z12)n-(A13-Z13)p-A14I and the use and preparation thereof and the preparation of 1,3-dioxane compounds.